YABAO PHARM.CORP(SH:600351) Xin Lang Cai Jing·2025-10-13 08:13Core Viewpoint - The announcement highlights that the company's wholly-owned subsidiary, Beijing Yabao Biological Pharmaceutical Co., Ltd., has received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration, indicating a significant milestone for the company in the diabetes treatment market [1] Group 1: Product Approval - The Sitagliptin Metformin Extended-Release Tablets are approved for use in adult patients with type 2 diabetes [1] - The drug was developed by Merck Sharp Dohme and was approved for sale in the United States in 2012 [1] - The expected sales amount for the product in China in 2024 is approximately 921 million RMB [1] Group 2: Market Context - A total of 11 companies have received the registration approval for this drug in China [1] - The company has invested approximately 15.3284 million RMB in research and development for this product [1]